Meeting
2016 Gastrointestinal Cancers Symposium
Prognostic impact of primary tumor location on survival time in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus oxaliplatin-based chemotherapy: A subgroup analysis of the JACCRO CC-05/06.
Authors
Yu Sunakawa
Division of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan
Yu Sunakawa , Wataru Ichikawa , Akihito Tsuji , Tadamichi Denda , Yoshihiko Segawa , Yuji Negoro , Ken Shimada , Mitsugu Kochi , Masato Nakamura , Masahito Kotaka , Hiroaki Tanioka , Akinori Takagane , Satoshi Tani , Tatsuro Yamaguchi , Masahiro Takeuchi , Masashi Fujii , Toshifusa Nakajima
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 613)
DOI
10.1200/jco.2016.34.4_suppl.613
Abstract #
613
Poster Bd #
F18
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Alteration of ADCC-related genes as a novel predictor of efficacy of cetuximab (cet)-based chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC) (JACCRO CC-05/06 AR).
First Author: Yu Sunakawa
Poster
2019 Gastrointestinal Cancers Symposium
Early tumor shrinkage and depth of response as predictors of favorable treatment outcomes in patients with metastatic colorectal cancer treated with FOLFOX/FOLFIRI plus cetuximab.
First Author: S.P. Somashekhar
Poster
2017 Gastrointestinal Cancers Symposium
CEA response and depth of response (DpR) to predict clinical outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line cetuximab plus oxaliplatin-based chemotherapy: A sub-analysis of the JACCRO CC-05/06 trials.
First Author: Yu Sunakawa
Poster
2015 ASCO Annual Meeting
A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405.
First Author: Federico Innocenti